Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

GHRP-6

Growth Hormone Releasing Peptide-6, Growth hormone-releasing hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2

Quick Stats
Studies 702
Trials 0
Score 3
2007 pubmed

In vitro release study of mono-PEGylated growth hormone-releasing peptide-6 from PLGA microspheres.

Park. Eun Ji EJ; Na. Dong Hee DH; Lee. Kang Choon KC

Key Findings

  • PEGylating GHRP‑6 reduces the initial burst release from PLGA microspheres.
  • The PEG‑GHRP‑6 formulation shows a near zero‑order (steady) release for up to one month in vitro.
  • Smaller PEG chains lead to faster drug release, while larger PEG chains slow it down.

Practical Outcomes

  • For DIY biohackers interested in long‑acting peptide dosing, this study suggests that attaching a PEG group to GHRP‑6 and encapsulating it in PLGA microspheres could create a month‑long delivery system. The choice of PEG size lets you tune how quickly the peptide becomes available, offering a potential way to reduce injection frequency. However, the results are still in vitro, so real‑world efficacy and safety still need to be tested.

Summary

Researchers tested a way to make the peptide GHRP‑6 release slowly over time by attaching a small PEG molecule and putting it into biodegradable PLGA microspheres. In lab tests, the PEG‑modified version leaked less at first and then released the peptide at a steady rate for about a month, with the speed of release changing depending on how big the PEG tag was.

Abstract

The purpose of this study was to investigate in vitro release property of mono-PEGylated growth hormone-releasing peptide-6 (GHRP-6) microspheres. The microspheres encapsulating native GHRP-6 or mono-PEG-GHRP-6 were prepared using the single oil-in-water emulsion solvent evaporation method. In vitro release study was performed in 0.1M phosphate buffer, pH 7.4, containing 0.02% Tween 80 and sodium azide at 37 or 55 degrees C. The mono-PEG-GHRP-6 microspheres showed a lower initial burst compared with native GHRP-6 microspheres and zero-order release profile for a 1-month period. The release period was dependent on the PEG size attached to the GHRP-6 with more rapid drug release being observed with the smaller PEG size. This study suggests that PEGylated peptide has good potential as a source for a sustained release microsphere delivery system.

Study Information

Provider

pubmed

Year

2007

Date

2007-06-14T00:00:00.000Z

DOI

10.1016/j.ijpharm.2007.06.005